
**Disclaimer**  

EN: This MD file was generated automatically through conversion of the HTML source served by the Federal Publishing Platform [Fedlex](https://www.fedlex.admin.ch/).
During this process, certain elements of the original source such as footnotes, tables or pictures can be lost or transformed incorrectly. Any inaccuracies present in the HTML source will be carried over to the MD file.  

DE: Diese MD Datei wurde durch automatische Konvertierung des auf der Publikationsplattform des Bundes [Fedlex](https://www.fedlex.admin.ch/) publizierten HTML Quelltextes erstellt.
Dieser Konvertierungsprozess kann dazu führen, dass gewisse Elemente wie bspw. Fussnoten, Tabellen oder Bilder falsch dargestellt werden oder verloren gehen.
Allfällige inkorrekte Passagen im HTML Quelltext werden in die MD Datei übernommen.  

EN: This is not an official publication. Only the official publication by the [Federal Chancellery](https://www.bk.admin.ch/bk/en/home.html) is authorative and legally binding.  
DE: Dies ist keine amtliche Veröffentlichung. Massgebend ist allein die Veröffentlichung durch die [Bundeskanzlei](https://www.bk.admin.ch/bk/de/home.html).  
FR: Ceci n’est pas une publication officielle. Seule la publication opérée par la [Chancellerie fédérale](https://www.bk.admin.ch/bk/fr/home.html) fait foi.  
IT: presente documento non è una pubblicazione ufficiale. Fa unicamente fede la pubblicazione della [Cancelleria federale](https://www.bk.admin.ch/bk/it/home.html).  

&nbsp;

----

&nbsp;

818.101.24

English is not an official language of the Swiss Confederation. This translation is provided for information purposes only, has no legal force and may not be relied on in legal proceedings.

# Ordinance 3on Measures to Combat the Coronavirus (COVID-19)

## (COVID-19 Ordinance 3)

of 19 June 2020 (Status as of 2 May 2022)

The Swiss Federal Council,

based on Articles 3, 4, 5 letters a and b and 8 of the COVID-19 Act of   
25 September 2020,   
on Article 63 paragraph 3 of the Therapeutic Products Act of 15 December 2000,  
and on Article 41 paragraph 1 of the Epidemics Act of 28 September 2012   
(EpidA),

ordains:

# [Chapter 1 General Provisions](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_1)

[**Art. 1** Subject matter and purpose](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_1) 

[1] This Ordinance orders measures applicable to the population, organisations and institutions and the cantons to combat the coronavirus (COVID-19).

[2] The measures serve to ensure Switzerland’s capacities to manage the epidemic, in particular to maintain the provision of the population with adequate care and a sufficient supply of essential medical goods.

[**Art. 2** Responsibility of the cantons](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_2) 

Unless this Ordinance provides otherwise, the cantons shall retain their responsibilities.

# [Chapter 2 Maintenance of Capacities to provide Healthcare](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_2)


## [Section 1 Principle](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_2/sec_1)

[**Art. 3**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_3) 

[1] In order to maintain Switzerland’s capacities to manage the COVID-19 epidemic and in particular to guarantee the provision of the population with adequate care and a sufficient supply of essential medical products, the following measures in particular must be taken: 


|    a. measures to restrict the entry of persons from high-risk countries and regions and the import and export of goods;  
|    b. measures to guarantee the provision of essential medical goods.

[2] High-risk countries or regions are countries or regions in which the coronavirus Sars-CoV-2 has been detected and in which:


|    a. there is an increased risk of infection; or  
|    b. a variant of the virus is widespread that carries a higher risk of infection or causes a more severe form of the disease in comparison with the variant of the virus that is prevalent in the Schengen area.

[3] The lists of high-risk countries and regions is published in Annex 1.

## [Section 2 Restrictions on Border Crossings and the Admission of Foreign Nationals](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_2/sec_2)


[**Art. 4**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_4) [Border crossings and controls](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_4) 

[1] The following persons shall be refused entry for a period of stay of up to three months that does not require a permit and does not involve gainful employment (Art. 10 of the Foreign Nationals and Integration Act of 16 December 2005 (FNIA):


|    foreign nationals who wish to enter Switzerland from a high-risk country or from a high-risk region and who do not fall within the scope of the Agreement of 21 June 1999 between the European Community and its Member States, of the one part, and the Swiss Confederation, of the other part, on the Free Movement of Persons (AFMP) or of the Convention of 4 January 1960 establishing the European Free Trade Association (EFTA Convention);   
|    b. and c. ... .

[2] The following persons are exempt from this ban on entry:


|    a. persons who prove that they have been vaccinated against Sars-CoV-2; the persons who are regarded as having been vaccinated, the period for which the vaccination is valid, and the accepted forms of proof are regulated in Annex 1*a* number 1;   
|    a[bis]. persons who prove that they have been infected with Sars-CoV-2 and have recovered; the period for which exemption is valid and the accepted forms of proof are regulated in Annex 1*a* number 2;   
|    b. persons who provide credible evidence that they are in a situation of special necessity;  
|    c. persons under the age of 18. 

[2bis] ...

[2ter] The exemptions under paragraph 2 letters a, a[bis] and c do not apply to persons who wish to enter Switzerland from a country or region listed in Annex 1 number 2. 

[2quater] The State Secretariat for Migration (SEM) shall issue the required directives on exceptions to the ban on entry.

[3] Decisions taken by the competent authorities may be enforced immediately. Article 65 of the FNIA applies *mutatis mutandis*. An appeal may be filed against the SEM decision within 30 days of notification. The appeal does not have suspensive effect.

[4] The criminal provisions of Article 115 FNIA apply *mutatis mutandis*. In the event of any violation of the provision on entry, a ban on entry may also be imposed.

[**Art. 5**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_5) [Updating the annexes](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_5) 

The Federal Department of Justice and Police (FDJP) shall update Annexes 1 and 1*a* continuously in consultation with the Federal Department of Home Affairs (FDHA) and the Federal Department of Foreign Affairs (FDFA).

[**Art. 6** and **7**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_6)

[**Art. 8**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_8)

[**Art. 9** Provisions on cross-border movements of persons and goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_9) 

[1] The FDJP in consultation with the FDHA, the Federal Department of the Environment, Transport, Energy and Communications (DETEC), the FDF and the FDFA shall decide on restrictions on air passenger services from high-risk countries or regions.

[2] It may in particular suspend passenger movements for certain flights, close individual airfields with international borders to passenger movements from high-risk countries or regions or prohibit movements of persons to Switzerland from high-risk countries or regions entirely.

[3] Restrictions on cross-border movements of persons are set out in Annex 2.

[**Art. 10**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_10) [Granting of visas](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_10) 

Foreign nationals who wish to enter Switzerland from a high-risk country or from a high-risk region and who do not fall within the scope of the AFMP or the EFTA Convention shall not be granted a Schengen visa for periods of stay of up to three months that do not require a permit and do not involve gainful employment. Exempted from the foregoing are applications from persons under Article 4 paragraph 2.

[**Art. 10***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_10_a) [Extension of deadlines](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_10_a) 

[1] Foreign nationals who have been prevented from acting within the deadlines laid down in Articles 47 or61 FNIA because of measures in connection with the coronavirus may carry out the act required at any time while this Ordinance remains in force.

[2] By carrying out the required act, they shall achieve the position that would have been achieved had they acted within the prescribed deadline.

[3] If the deadlines under Articles 59*b* or 102*a* FNIA for updating biometric data in order to obtain or extend a permit cannot be met because of the coronavirus, the permit may still be issued or extended at any time while this Ordinance remains in force.

## [Section 3 Provision of Essential Medical Goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_2/sec_3)

[**Art. 11** Definition](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_11) 

[1] Medicinal products, medical devices and protective equipment (essential medical goods) that are important and urgently needed to prevent and combat the coronavirus (COVID-19) are the goods listed in Annex 4.

[2] The Federal Department of Home Affairs (FDHA) is responsible for the list and shall update the same regularly in consultation with the Interdepartmental Working Group on Medical Goods in accordance with Article 12 and the Spiez Laboratory.

[3] The Federal Office of Public Health (FOPH) shall define the goods that need to be procured and how they should be used. Based on these terms of reference, the FOPH shall determine the quantities required in consultation with:


|    a. the Interdepartmental Working Group on Medical Goods: for active substances and drugs, medical devices, personal protective equipment and other equipment;  
|    b. the Spiez Laboratory: for COVID-19 tests and associated reagents.

[**Art. 12** Interdepartmental Working Group on Medical Goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_12) 

[1] The Interdepartmental Working Group on Medical Goods shall comprise as a minimum representatives from the following federal agencies:


|    a. the FOPH;  
|    b. the Therapeutic Products Division of the Federal Office for National Economic Supply;  
|    c. the Swiss Agency for Therapeutic Products (Swissmedic);  
|    d. the National Emergency Operations Centre (NEOC);  
|    e. the Medical Services Coordination Committee (SANKO) for Resources Management at Federal Level (ResMaB);  
|    f. the Armed Forces Pharmacy;  
|    g. the Coordinated Medical Services (CMS).

[2] The Federal Council CMS delegate chairs the working group.

[**Art. 13** Duty to report](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_13) 

[1] The cantons are obliged on request to report to the CMS on the current stocks of essential medical goods in their healthcare facilities.

[2] Laboratories and manufacturers and distributors of in vitro diagnostics (COVID-19 tests) are obliged to report regularly to the Spiez Laboratory on their current stocks of such tests.

[3] The CMS may request details of stocks from companies that store essential medical goods.

[**Art. 14** Procurement of essential medical goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_14) 

[1] In order to support the provision of essential medical goods to the cantons and their healthcare facilities, charitable organisations (for example Swiss Red Cross) and third parties (for example laboratories, pharmacies), essential medical goods may be procured if requirements cannot be covered through the normal procurement channels.

[2] The essential medical goods that are required shall be determined on the basis of the data transmitted in accordance with Article 13.

[3] The Armed Forces Pharmacy is responsible for procuring essential medical goods under paragraph 1 on behalf of the FOPH.

[4] The responsible authorities may delegate the procurement of essential medical goods to third parties.

[5] When procuring essential medical goods, the Armed Forces Pharmacy may take calculated risks and diverge from the provisions of existing directives and the Financial Budget Act of 7 October 2005 in relation to risks, such as prepayment without security or currency hedging.

[6] The Armed Forces Pharmacy manages the procured essential medical goods as instructed by the Interdepartmental Working Group on Medical Goods.

[**Art. 15** Allocation of essential medical goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_15) 

[1] The cantons shall submit requests for allocation to the ResMaB as required.

[2] Allocation shall be made continuously based on the supply situation and the current number of cases in each canton.

[3] The CMS in consultation with Interdepartmental Working Group on Medical Goods may allocate essential medical goods to the cantons, to charitable organisations and to third parties.

[4] The Spiez Laboratory in consultation with the FOPH is responsible for allocating in vitro diagnostics (COVID-19 tests). Allocation when required applies to all tests available in Switzerland.

[**Art. 16** Delivery and distribution of essential medical goods](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_16) 

[1] The Confederation or the third parties that it instructs shall ensure the delivery of the essential medical goods procured under Article 14 to a distribution centre for each canton. In exceptional cases, the Confederation in consultation with the cantons may supply eligible facilities and organisations directly.

[2] The cantons shall designate cantonal distribution centres for goods that are not supplied directly to the recipient, and shall give notice of these to the responsible federal authorities.

[3] They shall ensure that essential medical goods that have been delivered are distributed as required and in good time on their territory.

[**Art. 17** Direct sales by the Confederation](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_17) 

The Confederation may sell the essential medical goods on the market in return for payment, either itself or through third parties.

[**Art. 18** Costs](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_18) 

[1] The costs of procuring essential medical goods shall be funded in advance by the Confederation in the cases where it procures the goods.

[2] The cantons, charitable organisations and third parties shall notify the Confederation as quickly as possible of the purchasing costs of the essential medical goods supplied to them where the Confederation has assumed responsibility for their procurement in accordance with Article 14 paragraph 1.

[3] The Confederation shall bear the costs of delivering the procured essential medical goods to the cantons.

[4] The cantons shall bear the costs of distributing these essential medical goods within the canton.

[5] If the procured goods become freely available in the market again, the Confederation may sell its stocks at market prices.

[**Art. 19** Requisitioning](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_19) 

[1]If the provision of essential medical goods cannot be guaranteed, the FDHA at the request of the Interdepartmental Working Group on Medical Goods may require individual cantons or public healthcare facilities that have adequate stocks of medicinal products under Annex 4 number 1 to deliver part of their stocks to other cantons or healthcare facilities. The cantons or healthcare facilities shall charge the recipient directly for the costs of the goods and their delivery at the sale price.

[2] Subject to the requirement of paragraph 1, the FDHA at the request of the Interdepartmental Working Group on Medical Goods may order the requisitioning of essential medical goods held by companies. The Confederation shall pay compensation at the sale price.

[**Art. 20** Manufacture](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_20) 

[1]If the provision of essential medical goods cannot otherwise be guaranteed, the Federal Council at the request of the Interdepartmental Working Group on Medical Goods may require manufacturers to produce essential medical goods, to prioritise the production of such goods or to increase production volumes.

[2]The Confederation may contribute to the cost of production under paragraph 1 where manufacturers suffer financial disadvantages as a result of the changeover in production or the cancellation of private orders.

[**Art. 21** Exceptions to the requirement of authorisation for medicinal products](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_21) 

[1] Medicinal products that are manufactured with active substances under Annex 5 for the treatment of COVID-19 patients may, provided an application for authorisation of a medicinal product containing one of these active substances has been filed, be placed on the market without authorisation pending Swissmedic’s decision on authorisation. When examining applications for authorisation, Swissmedic may permit a relaxation of the relevant requirements for such medicinal products under the law on therapeutic products on the basis of a risk-benefit analysis.

[1bis] Medicinal products that are manufactured with active substances under Annex 5*a* in order to prevent the COVID-19 infection of immunosuppressed persons in whom sufficient immune protection cannot be built up despite vaccination or who cannot be vaccinated may be placed on the market without authorisation after submission of an application for the authorisation of a medicinal product containing any of these active substances until Swissmedic's decision on the authorisation has been taken.

[2] Amendments to the authorisation for a medicinal product authorised in Switzerland containing an active substance under Annex 4 number 1 on the basis of which the medicinal product can be used to treat COVID-19 patients in Switzerland may be made immediately after filing a corresponding amendment application and pending Swissmedic’s decision on authorisation. Swissmedic may, on the basis of a risk-benefit analysis, permit a relaxation of the relevant requirements under the law on therapeutic products for amendments to the authorisation of medicinal products containing an active substance listed in Annex 4 number 1.

[3]The FDHA shall regularly update the lists in Annexes 5 and 5*a*.

[4]Swissmedic may on the basis of a risk-benefit analysis permit changes to the manufacturing process approved within the framework of the authorisation of medicinal products used to prevent and treat COVID-19 in Switzerland. It shall specify criteria according to which the person responsible for technical matters may grant an early market release for medicinal products used to prevent and treat COVID-19 in Switzerland.

[5] In derogation from Article 9*a* paragraph 1 letter c of the Therapeutic Products Act of 15 December 2000, temporary authorisations may be issued even if an authorised equivalent medicinal product that can be used as an alternative is available in Switzerland, provided the authorisations serve to guarantee the supply of medicinal products to prevent and combat the coronavirus in Switzerland.

[**Art. 22** Exceptions to the provisions on the import of medicinal products](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_22) 

[1] Following the submission of a authorisation application for a medicinal product containing active substances listed in Annex 5 for the treatment of Covid 19 patients, the applicant may import the medicinal product prior to its authorisation or entrust the import of the medicinal product to a company with a wholesale or import licence.

[1bis] Pharmacists that have pharmaceutical responsibility in a hospital pharmacy may import non-authorised medicinal products with active substances under Annex 5 for the treatment of COVID-19 patients. A company with a wholesale or import licence may be instructed to import such medicinal products.

[2] Notice of each import under paragraph 1bis must be given to Swissmedic within 10 days of the arrival of goods.

[2bis] After submitting an application for the authorisation of a medicinal product in accordance with Article 21 paragraph 1[bis], the applicant may import the medicinal product or instruct a company with a wholesale or import licence to import it before authorisation is granted.

[3] In order to prevent and treat COVID-19 in Switzerland, Swissmedic may allow the temporary placing on the market of a medicinal product as a short-term solution for the temporary non-availability of an identical medicinal product authorised in Switzerland, provided no essentially identical medicinal product is authorised and available in Switzerland.

[4] After submitting its application for authorisation for a COVID-19 vaccine and for an operating licence under Article 10 paragraph 1 letter b of the Therapeutic Products Act of 15 December 2000, the applicant may instruct a company with a wholesale or import licence to import the COVID-19 vaccine before its authorisation and to store the vaccine until authorisation is granted. The company instructed must comply with the international rules on good distribution practice in accordance with Annex 4 of the Medicinal Products Licensing Ordinance of 14 November 2018.

[**Art. 23** Exceptions for medical devices](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_23)

[1] In response to an application, Swissmedic may authorise the placing on the market and use of medical devices that have not undergone a conformity assessment procedure in accordance with Article 23 the Medical Devices Ordinance of 1 July 2020[46](https://www.fedlex.admin.ch/eli/cc/2020/438/en#fn-d6e1117) (MedDO), provided their use for preventing and combating the coronavirus in Switzerland is in the interests of public health or patient safety or health and provided, taking account of their intended purpose, their fulfilment of the essential requirements and their effectiveness and performance are adequately proven.

[2] When assessing the risks under paragraph 1, Swissmedic shall in particular take account of the procurement needs identified by the FOPH for preventing and combating the coronavirus in Switzerland.

[3] Authorisation shall be granted to the Swiss distributor or the applicant institution or healthcare facility. It may be made subject to a time limit and other conditions and requirements.

[4] Facemasks which have not undergone a conformity assessment procedure under Article 23 MedDO may be placed on the market without authorisation under paragraph 1 provided they:


|    a. are placed on the market exclusively for non-medical use; and  
|    b. are expressly labelled as being for non-medical use.

[5] Facemasks placed on the market in accordance with paragraph 3[bis] may not be used in hospitals or medical practices by persons in direct contact with patients.

[5bis] The SwissCovid app as specified in the Ordinance of 24 June 2020 on the Proximity Tracing System for the Coronavirus Sars-CoV-2 and as specified in the Ordinance of 30 June 2021 on a Notification System for possible Infection with the Coronavirus Sars-CoV-2 at Events is not subject to the provisions on the conformity assessment of medical devices.

[6] The obligations in relation to product surveillance under the MedDO, in particular to collecting reports of incidents, continue to apply.

[**Art. 23***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_23_a)

[**Art. 23***b*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_23_b) [Exception for FFP masks](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_23_b) 

[1] FFP masks that do not comply with the principles and procedures for conformity assessment under Article 3 paragraph 2 of the PPE Ordinance of 25 October 2017 (PPEO) and whose non-compliance with these principles and procedure has not been approved based on Article 24 paragraph 3 in its version of 22 June 2020 may not be placed on the market.

[2] FFP masks under paragraph 1 held in federal and cantonal stocks may be supplied to private hospitals, homes for the elderly and care homes and organisations that provide nursing services and other assistance at home as well as to federal and cantonal facilities such as the armed forces, civil defence units, hospitals and prisons provided the federal or cantonal authority responsible for the supply:


|    a. guarantees by means of testing by a recognised European conformity assessment body for FFP masks that the masks provide a level of safety equivalent to that legally required under the PPEO; and  
|    b. guarantees their traceability.

[3] Product information in at least one official language or in English must be available when the masks are supplied. It must be ensured that the user is able to use the product in accordance with the relevant provisions.

[**Art. 24**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24) [Sars-CoV-2 rapid tests for specialist use and the supply and use of Sars-CoV-2 self-tests](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24)

[1] Non-automated single-patient rapid tests for direct detection of Sars-CoV-2 (Sars-CoV-2 rapid tests) for specialist use may only be carried out in the following facilities:


|    a. laboratories licensed under Article 16 of the Epidemics Act of 28 September 2012 (EpidA) and sample collection stations that they operate;  
|    b. medical practices, pharmacies and hospitals, homes for the elderly and care homes and socio-medical institutions, and test centres operated by or on behalf of the canton.

[1bis] They may also be carried out in and by organisations that provide nursing services and other assistance at home as well as by assistants as defined in the Federal Act of 19 June 1959 on Invalidity Insurance (InvIA).

[2] Sars-CoV-2 rapid tests may also be carried out at a location outside the facilities mentioned in paragraph 1 provided a laboratory manager, a doctor or a pharmacist accepts responsibility for complying with the requirements of this article and Articles 24*a* and 24*b*. 

[3] If facilities under paragraph 1 letter a offer Sars-CoV-2 rapid tests at a location outside the facilities, they must notify the canton of their offer. 

[4] Facilities under paragraphs 1 letter b and 1[bis] may carry out Sars-CoV-2 rapid tests for specialist use without a licence under Article 16 EpidA and outside closed systems provided they comply with the following conditions:


|    a. Suitable safety measures and precautionary measures plans to protect persons, animals, the environment and biological diversity have been prepared and implemented.  
|    b. The tests are only carried out by persons specifically trained for this purpose according to the instructions provided by the test manufacturer.   
|    c. The test results are interpreted under the supervision of persons with the required expertise; external experts may also be consulted.  
|    d. The facilities keep records that permit the traceability and prove the quality of the test systems used. The records must be preserved.  
|    e. The facilities are authorised by the canton to carry out such tests.

[4bis] Sars-CoV-2 rapid tests for self-testing by the public (Sars-CoV-2 self-tests) may be supplied and used if they are intended for self-testing by the manufacturer and certified accordingly. 

[5] Sars-CoV-2 rapid tests are direct detection methods that detect the antigens to Sars-CoV-2. The tests are not automated and are carried out with the minimum of instruments; only the reading of the test result may be automated. 

[**Art. 24***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_a) [Permitted Sars-CoV-2 rapid tests for specialist use](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_a) 

[1] The only test systems that may be used for Sars-CoV-2 rapid tests for specialist use are those authorised in the EU for issuing the EU’s digital COVID certificate.

[2] In derogation from paragraph 1, other test systems may also be used provided the Sars-CoV-2 rapid tests are carried out by laboratories licensed under Article 16 EpidA and the sample collection stations that they operate.

[**Art. 24***b*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_b) [Notifying the canton of a positives test result in the absence of a confirmatory diagnosis](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_b) 

If no confirmatory diagnosis is made following a positive result for a Sars-CoV-2 rapid test and if the FDHA has not required a report on the result of Sars-CoV-2 rapid tests on the basis of Article 19 of the Epidemics Ordinance of 29 April 2015, the facility or person responsible for conducting the tests must notify the cantonal authority or organisation responsible for contact tracing of the positive test result.

[**Art. 24***c*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_c) [Lists of Sars-CoV-2 rapid tests](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_c) 

The FOPH shall maintain continuously updated lists of Sars-CoV-2 rapid tests for specialist use in accordance with Article 24*a* and theSars-CoV-2 self-tests in accordance with Article 24 paragraph 4[bis] and shall publish the lists on its website.

[**Art. 24***d*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_d) [Responsibility of the cantons for carrying out Sars-CoV-2 rapid tests](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_d) 

The cantons are responsible for monitoring and enforcing compliance with the conditions in Articles 24–24*b* for Sars-CoV-2 rapid tests that are not carried out at the facilities referred to in Article 24 paragraph 1 letter a.

[**Art. 24***e*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_e) [Collecting samples for molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_e) 

[1] Samples for molecular-biological analyses for Sars-CoV-2 may be collected:


|    a. in laboratories licensed under Article 16 EpidA and in sample collection stations that they operate;   
|    b. in facilities or by persons in accordance with Article 24 paragraphs 1 letter b, 1[bis] and 2;  
|    c. in other sample collection stations, provided the samples are collected under the supervision of laboratories licensed under Article 16 EpidA and the sample collection station has notified the canton that it is carrying out this activity.

[2] The sample collection station must verify the identity of the person being tested. The sample must be collected by a person trained for this purpose.

[3] The sample may also be collected by the person being tested themselves:


|    a. in the facility, provided the facility verifies the identity of the person being tested and supervises the collection of the sample as it is being done; or  
|    b. outside the facility, provided the facility verifies the identity of the person being tested and guarantees that the sample is correctly assigned to the person being tested by taking suitable precautions, in particular by the video monitoring of the process.

[**Art. 24***f*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_f) [Responsibility for monitoring the collection of samples for molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_f) 

Swissmedic is responsible for monitoring compliance with the requirements set out in Article 24*e* by laboratories licensed under Article 16 EpidA, including the collection of samples carried out under the supervision of such laboratories by facilities in accordance with Article 24*e* paragraph 1 letter c, and the cantons are responsible for monitoring in the facilities in accordance with Article 24*e* paragraph 1 letter b and for the supervision of collection stations in accordance with Article 24*e* paragraph 1 letter c.

[**Art. 24***f*[bis]](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_f_bis) [Conducting molecular-biological analyses for Sars-CoV-2 abroad](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_f_bis) 


Only laboratories with a licence under Article 16 EpidA may commission a foreign laboratory to conduct molecular-biological analyses for Sars-CoV-2. They remain subject to the requirement to report under Article 12 EpidA.

[**Art. 24***g*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_g) [Disclosure of data](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_24_g) 

Swissmedic may disclose data on essential medical goods to the federal offices and organisations mentioned in Article 12 paragraph 1, provided this is required in order to implement this Ordinance. The data must not include sensitive personal data.

# [Chapter 3 Healthcare Provision](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_3)

[**Art. 25** Hospitals and clinics](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_25) 

[1] The cantons shall ensure that sufficient capacities (in particular beds and specialist staff) are available in the inpatient departments of hospitals and clinics for COVID-19 patients and for other urgently required medical examinations and treatments, in particular in the intensive care units and the general internal medicine departments.

[2] For this purpose, they may require hospitals and clinics:


|    a. to make their inpatient capacities available immediately or on demand; and  
|    b. to restrict or suspend non-urgent medical procedures and treatments.

[3] The hospitals and clinics must ensure that supplies of medicinal products for COVID-19 patients and for other urgently required medical examinations and treatments is guaranteed in their outpatient and inpatient departments.

[**Art. 25***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_25_a) [Duty of the cantons to report healthcare capacities](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_25_a) 

The cantons shall be required to report the following regularly to the Coordinated Medical Services:


|    a. the total number and occupancy of hospital beds;  
|    b. the total number and occupancy of hospital beds intended for treating COVID-19 patients, as well as the number of COVID-19 patients currently being treated;  
|    c. the total number and occupancy of intensive care beds and the number of COVID-19 patients currently being treated and being ventilated in intensive care;  
|    d. the total number and usage of extracorporeal membrane oxygenation devices (ECMO);  
|    e. the availability of medical and nursing staff in hospitals;  
|    f. the maximum capacities, i.e. the total number of patients and of COVID-19 patients that can be treated in their hospitals taking into consideration the numbers of available beds and of available staff.

[**Art. 26**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26) [Payment of costs for analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26) 

[1] The Confederation shall pay the effective costs of analyses for Sars-CoV-2 subject to the requirements and maximum amounts set out in Annex 6*.*

[2] Every week, the FOPH shall publish on its website the number of molecular-biological analyses for Sars-CoV-2 in accordance with Annex 6 number 1 that were conducted in the previous calendar week in Switzerland and in Liechtenstein. The FDHA may adjust the maximum amounts paid in line with the effective costs.

[3] For analyses for Sars-CoV-2 under Annex 6, the order to the laboratory must include the information required for electronic invoicing, in particular the tested person’s health insurance number or client number.

[4] Persons tested as specified in Annex 6 shall not be required to pay a share of the costs in accordance with Article 64 of the Federal Act of 18 March 1994 on Health Insurance (HIA).

[5] Service providers shall not charge persons tested as specified in Annex 6 any additional costs. They must pass on any sums that directly or indirectly cover any part of the cost shares in accordance with Annex 6 to the reimbursement debtor.

[6] If the service provider offers services in accordance with Annex 6 that must be paid for by the person tested, it must inform the person concerned before carrying out the test that the costs may be covered under Article 26*b*.

[**Art. 26***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_a) [Persons liable to pay for the services](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_a) 

[1] Where a service involving an analysis for Sars-CoV-2 under Annex 6 number 1 is carried out by a service provider that has a paying agent register number (ZSR number), payment for the service shall be made under the *tiers payant* system in Article 42 paragraph 2 HIA by the following insurers:


|    a. in the case of persons who have mandatory health insurance under the HIA, by the health insurance company under Article 2 of the Health Insurance Oversight Act of 26 September 2014 with which the person tested is insured;  
|    b. in the case of persons who have military insurance against illness, by the military insurance;  
|    c. in the case of persons who do not have mandatory health insurance under the HIA, and in the case of persons who have died, by the Joint Institution under Article 18 HIA.

[2]Where a service involving an analysis for Sars-CoV-2 under Annex 6 number 1 is carried out by a service provider that does not have a ZSR number, the canton in which the sample is taken shall pay for the services.

[3] In the case of analyses for Sars-CoV-2 in accordance with Annex 6 numbers 1.1 and 1.4 following a positive result from a pooled molecular-biological analysis or based on an outbreak investigation ordered by a doctor and in the case of analyses in accordance with Annex 6 numbers 3.1.1 letter a and 3.2.1 letter a, the service providers may choose as the person liable to pay for the service:


|    a. the insurer under paragraph 1 that is liable to pay for the services under the *tiers payant* system in terms of Article 42 paragraph 2 HIA; or  
|    b. the canton in which the sample for Sars-CoV-2 is taken.

[4]Where the analysis for Sars-CoV-2 under Annex 6 Sections 2, 3.1.1 letters b–d and 3.2.1 letters b and c is conducted, the canton in which the sample for Sars-CoV-2 is taken shall pay for the services.

[**Art. 26***b*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_b) [Procedure where the insurer is liable to pay for the service](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_b) 

[1]Where an insurer is liable to pay for the service under Article 26*a* paragraphs 1 and 3 letter a, the service providers under Article 26 paragraph 2 shall send an invoice for services under Annex 6 for each person tested to the insurer concerned on a case-by-case basis or collectively every quarter at the latest nine months after providing the services. The invoice may only cover services under Annex 6. The invoice shall preferably be sent electronically.

[2] Service providers shall not charge for services under Annex 6 as Positions 3186.00, 3188.00 and 3189.00 of Annex 3 to the Health Insurance Benefits Ordinance of 29 September 1995 (HIBO).

[3] The insurers shall check the invoices and ascertain whether the service provider has charged correctly for the services under Annex 6. They shall comply with Articles 84–84*b* HIA in processing the data.

[4] At the start of January, April, July and October, they shall notify the FOPH of the number of analyses for which they have paid the service providers, and of the amount paid in each case. The external auditors for the insurers shall each year review the figures and confirm that suitable checks in accordance with paragraph 3 are being made and submit a report to the FOPH. The FOPH may request additional information from the insurers on the amounts paid to each service provider.

[5] The Confederation shall reimburse the insurers every quarter for the services that they have paid for.

[6] If the invoice for the service sent by the service provider is incorrect, the insurer may claim back any payments already made. Once the Confederation has paid for the service in accordance with paragraph 5, the right to reimbursement passes to the Confederation. The insurers shall provide the Confederation with the data required to exercise its right to reimbursement. The data may not include any sensitive personal data.

[6bis] and[6ter] ...

[7] The joint institution shall invoice the FOPH every quarter on a time and material basis for the administrative costs of its activities as an insurer under Article 26*a* paragraphs 1 letter c and 3 letter a. The hourly rate shall be 95 francs and includes salary costs, social insurance payments and infrastructure costs. The actual costs of any expenditure on audits, system modifications and negative interest not included in the administrative costs shall be reimbursed.

[8] Invoices for analyses for Sars-CoV-2 that meet the requirements of Annex 6 must be marked «Analysis for Sars-CoV-2 without meeting the testing criteria».

[**Art. 26***c*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_c) [Procedure where the canton is liable to pay for the service](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_26_c) 

[1]Where the canton is liable to pay for the service under Article 26*a* paragraphs 2, 3 letter b and 4, the service providers shall send a collective invoice on a quarterly basis to the canton concerned no later than nine months after the services were provided. The invoice may only cover services under Annex 6. The invoice shall preferably be sent electronically.

[2] Service providers shall not charge for services under Annex 6 as Position 3186.00 of Annex 3 HIBO.

[3] The cantons shall check the invoices and ascertain whether the service provider has charged correctly for the services under Annex 6. They shall comply with the relevant cantonal data protection provisions.

[4] At the start of January, April, July and October, they shall notify the FOPH of the number of analyses for which they have paid the service providers, and of the amount paid in each case.

[5] The Confederation shall reimburse the cantons every quarter for the services that they have paid for. It shall also make a single start-up payment to cantons that arrange for the targeted and repetitive testing of their residents. The cantons shall invoice the Confederation for the actual costs of such testing only, up to a maximum of 8 francs per resident. Costs related to information technology and logistics may be included.

[6] If the invoice for the service sent by the service provider is incorrect, the insurer may claim back any payments already made. Once the Confederation has paid for the service in accordance with paragraph 5, the right to reimbursement passes to the Confederation. The insurers shall provide the Confederation with the data required to exercise its right to reimbursement. The data may not include any sensitive personal data.

# [Chapter 4 Company Meetings](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_4)

[**Art. 27**](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_27) 

[1] In the case of company meetings, the organiser may, regardless of the probable number of participants and without complying with the period of notice for convening meetings, order the participants to exercise their rights exclusively:


|    a. in writing or online; or  
|    b. through an independent proxy appointed by the organiser.

[2] Notification of the order must be given in writing or published online no later than four days before the event.

# [Chapter 4*a …*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_4_a)

[**Art. 27***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_27_a)

# [Chapter 5 Final Provisions](https://www.fedlex.admin.ch/eli/cc/2020/438/en#chap_5)

[**Art. 28** Repeal of another enactment](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28) 

The COVID-19 Ordinance 2 of 13 March 2020 is repealed.

[**Art. 28***a*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28_a) [Transitional provision to the Amendment of 11 September 2020](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28_a) 

Personal protective equipment that was permitted under Article 24 of the previous law may continue to be placed on the market until 30 June 2021.

[**Art. 28***b*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28_b) [Transitional provisions to the Amendment of 23 June 2021](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28_b) 

[1] …

[2] Pharmacies may continue to supply Sars-CoV-2 self-tests licensed under Article 23*a* of the previous law provided the requirements of Article 24 paragraph 4[bis] letter b are met.

[3] …

[**Art. 28***c*](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_28_c)

[**Art. 29** Commencement and term](https://www.fedlex.admin.ch/eli/cc/2020/438/en#art_29) 

[1] This Ordinance comes into force on 22 June 2020 at 00.00.

[2] It applies until 13 September 2020.

[3] ...

[4] The term of application of this Ordinance shall be extended to 31 December 2021, subject to paragraph 5.

[5] Article 27 applies until the provisions on the conduct of general meetings in the Amendment of 19 June 2020 to the Swiss Code of Obligations (Company Law) comes into force, but at the latest until 31 December 2023.

[6] The term of application of this Ordinance shall be extended to 31 December 2022, subject to paragraphs 5 and 7.

[7] Article 27*a* and Annex 7 apply until 31 March 2022.

# [Annex 1](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1)

(Art. 3 para. 3, 4 para. 2[ter] and Art. 5)

## [List of high-risk countries and regions](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1/lvl_d4e65)

### [1. High-risk countries and regions (Art. 3 para. 2 let. a)](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1/lvl_d4e65/lvl_1)

*There are no entries currently on this list*

### [2. High-risk countries and regions with a variant of the Sars-CoV-2 virus that carries a higher risk of infection or causes a more severe form of the disease in comparison with the variant of the virus prevalent in the Schengen area (Art. 3 para. 2 let. b)](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1/lvl_d4e65/lvl_2)

*There are no entries currently on this list*

# [Annex 1a](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1_a)

(Art. 4 para. 2 let. a and a[bis] and Art. 5)

## [Persons who have been vaccinated and who have recovered](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1_a/lvl_d4e69)

### [1 Persons who have been vaccinated](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1_a/lvl_d4e69/lvl_1)


|    1.1 Persons who have been vaccinated are persons who have been vaccinated with a vaccine that:  
|    a. is authorised in Switzerland and which has been administered in full in accordance with the FOPH recommendations;  
|    b. has been authorised by the European Medicines Agency for the European Union and has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was administered;   
|    c. has been authorised under the WHO Emergency Use Listing and has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was administered; or  
|    d. has been shown to have the same composition as a vaccine licensed under letters a, b or c, but marketed by the licence holder under another name, and which has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was carried out.


|    1.2 A vaccination is valid for 270 days from the date of vaccination in full or from the date of a booster vaccination following vaccination in full; the Janssen Ad26.COV2.S / COVID-19 vaccine is regarded as being effective for 270 days from the 22nd day after it was administered in full.  
|    1.3 Proof of vaccination may be provided in the form of a COVID-19 certificate in accordance with Article 1 letter a number 1 of the COVID-19 Ordinance on Certificates of 4 June 2021 or a recognised foreign certificate in accordance with Section 7 of the COVID-19 Ordinance on Certificates.  
|    1.4 Proof may also be provided in a different form from that in number 3. It must be a form of proof that is customary at the time. In addition to the surname, forename and date of birth of the person concerned, it must include the following information:  
|    a. the date of vaccination;  
|    b. the vaccine used.



### [2 Persons who have recovered](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_1_a/lvl_d4e69/lvl_2)


|    2.1 Proof of recovery is valid for the following periods:  
|    a. in the case of a molecular-biological analysis for Sars-CoV-2: from the 11th to the 180th day following confirmation of the infection;  
|    b. in the case of a Sars-CoV-2 rapid test for specialist use or a laboratory-based immunological analysis for Sars-CoV-2, with the exception of tests and analyses based on a sample taken solely from the nasal cavity or on a saliva sample: from the 11th to the 180th day following confirmation of the infection;  
|    c. in the case of an analysis for Sars-CoV-2 antibodies: for the period of validity of the related certificate (Art. 34*a* para. 1 let. c of the COVID-19 Ordinance on Certificates of 4 June 2021);


|    2.2 Proof of recovery may be provided in the form of a COVID-19 certificate under Article 1 letter a number 2 of the COVID-19 Ordinance on Certificates or a recognised foreign certificate under Section 7 of the COVID-19-Ordinance of Certificates.  
|    2.3 Proof may also be provided in forms other than in Number 2.2. It must be a form of proof that currently commonly accepted. It must, in addition to the surname, first name(s) and date of birth of the person concerned contain either of the following:  
|    a. confirmation of the infection, including the name and address of the confirming body (test centre, doctor, pharmacy, hospital);  
|    b. confirmation of the termination of isolation or a doctor’s confirmation of recovery.



# [Annex 2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_2)

# [Annex 3](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_3)

(Art. 9 para. 3)

## [Restrictions on cross-border movements of persons](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_3/lvl_d4e75)

There are no entries currently on this list.

# [Annex 4](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76)

(Art. 11 para. 1, 19 para. 1 and 21 para. 2)

## [List of important medicinal products, medical devices and protective equipment (Essential Medical Goods)](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77)

### [1. Active substances or medicinal products with the listed active substances](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77/lvl_1)

1. Tocilizumab

2. Remdesivir

3. Propofol

4. Midazolam

5. Ketamine

6. Dexmedetomidine

7. Dobutamine

8. Sufentanil

9. Remifentanyl

10. Rocuronium

11. Atracurium

12. Suxamethonium

13. Noradrenalin

14. Adrenalin

15. Insulin

16. Fentanyl

17. Heparin

18. Argatroban

19. Morphine

20. Paracetamol (parenteral)

21. Metamizol (parenteral)

22. Lorazepam

23. Dexamethasone

24. Co-Amoxicillin

25. Piperacillin/Tazobactam

26. Meropenem

27. Imipenem/Cilastatin

28. Cefuroxime

29. Ceftriaxone

30. Amikacin

31. Posaconazole

32. Fluconazole

33. Voriconazole

34. Caspofungin

35. Esmolol (parenteral)

36. Metoprolol (parenteral)

37. Labetalol (parenteral)

38. Clonidine

39. Amiodarone

40. Furosemide

41. Vaccines against COVID-19

42. Vaccines against influenza

43. Vaccines against bacterial pneumonia (Prevnar 13)

44. Medical gases


|    45. Casirivimab/imdevimab

46. Nirmatrelvir (PF-07321332)/Ritonavir

47. Medical oxygen 

48. Infusion solutions

49. Sotrovimab

50. Tixagevimab/Cilgavimab

### [2. Medical devices within the meaning of the Medical Devices Ordinance of 17 October 2001](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77/lvl_2)

1. Ventilators

2. Monitoring equipment for intensive care

3. In vitro diagnostics (COVID-19 tests), including pre-analytical components and instruments

4. Surgical masks / OP masks (hygiene masks)

5. Surgical gloves / examination gloves

6. Infusion sets

7. Pipette tips with filters

8. Test kits (tubes and swabs)

9. Single-use syringes and cannulae

10. Blood gas syringes

### [3. Personal protective equipment and other equipment](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77/lvl_3)

#### [3.1 Personal protective equipment within the meaning of the PPE Ordinance of 25 October 2017](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77/lvl_3/lvl_d4e81)

1. Respirators (FFP2 and FFP3)

2. Aprons 

3. Protective overalls 

4. Protective eyewear 

5. Disposable caps

#### [3.2 Further equipment](https://www.fedlex.admin.ch/eli/cc/2020/438/en#lvl_d4e76/lvl_d4e77/lvl_3/lvl_d4e82)

1. Hand disinfectants 

2. Surface disinfectants 

3. Ethanol

4. Hygiene products for intensive care (such as absorbent pads, diapers, faecal collectors, oral hygiene items)

# [Annex 5](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_5)

(Art. 21 paras 1 and 3, as well as 22 para. 1)

## [List of active substances for the treatment of COVID-19](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_5/lvl_d4e84)


|    1. Nirmatrelvir PF-07321332)/Ritonavir  
|    2. Tixagevimab/Cilgavimab

# [Annex 5a](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_5_a)

(Art. 21 para. 1[bis] and 3)

## [List of active substances that prevent COVID-19 infection](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_5_a/lvl_d4e87)

1. Tixagevimab/Cilgavimab

# [Annex 6](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6)

(Art. 26, 26*a*, 26*b* and 26*c*)

## [Services and maximum amounts paid for Sars-CoV-2 analyses](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89)

### [1 Standard tariff for symptom- and case-based testing](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1)

#### [1.1 Molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e91)


|    1.1.1 The Confederation shall pay the costs of molecular-biological analyses for Sars-CoV-2 for persons who have symptoms. In the case of persons who are asymptomatic, it shall pay the costs of such analyses in the following cases only:  
|    a. …  
|    b. persons who have in any of the following periods lived in the same household as or in a similar way have had close contact with:  
|    1. a person whose infection with Sars-VoV-2 has been confirmed or is probable and who has symptoms: in the 48 hours prior to the appearance of symptoms and for 5 days thereafter,  
|    2. a person whose infection with Sars-VoV-2 has been confirmed but who is asymptomatic: in the 48 hours prior to the sample being taken and until the person went into isolation;


|    c. and d. …  
|    e. persons who have been notified by the SwissCovid app that they have potentially been in close contact with a person infected with Sars-CoV-2; the Confederation shall pay the costs of a single test;  
|    f. persons resident abroad who work, study or train in Switzerland, in cases where they are required to produce a negative molecular-biological test result for Sars-CoV-2 when entering their foreign country of residence and no other authority will cover the costs;  
|    g. persons resident in Switzerland who work, study or train abroad where they are required to produce a negative molecular-biological test result for Sars-CoV-2 when entering the foreign country concerned and no other authority will cover the costs;  
|    h. following a positive result from a:  
|    – Sars-CoV-2-rapid test for specialist use,  
|    – Sars-CoV-2 self-test;


|    i. following a positive result from a pooled molecular-biological analysis:  
|    1. in accordance with Number 1.2,  
|    2. in accordance with Numbers 1.7, 2.2 and 3.2;


|    j. as part of outbreak investigation and control procedures ordered by a doctor.


|    1.1.2 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample, by:  
|    1. the following service providers under the HIA:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 of the Ordinance of 27 June 1995on Health Insurance (HIO) and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA;


|    b. when an analysis is conducted, by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.


|    1.1.3 It shall pay a maximum of 153.50 francs of the cost of molecular-biological analyses for Sars-CoV-2. This amount covers the following services and cost components:  
|    a. for collecting a sample:





|  |  |
| --- | --- |
| Service | Maximum amount |
| Patient consultation and taking sample, including protective materials | 22.50 Fr. |
| For supervising the taking of the sample by the person tested and assigning the sample to the person concerned | 15 Fr. |
| Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA, and requesting the activation code generated by the Proximity Tracing System for the Coronavirus Sars-CoV-2 (PT System) when infection is detected and for issuing the COVID-19 test or recovery certificate |   2.50 Fr. |
| Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
|  |  |


|    b. for the molecular-biological analysis:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If conducted on behalf of another service provider, comprising:|    – analysis and report to the authorities under Article 12 paragraph 2 EpidA, if the number of analyses conducted in Switzerland and Liechtenstein during a calendar week amounts to: | 106 Fr. |
| |    – < 100 000 |   82 Fr. |
| |    – 100 000 – < 150 000 |   74 Fr. |
| |    – 150 000 – < 200 000 |   70 Fr. |
| |    – > 200 000 |   64 Fr. |
| |    – ordering processing, overheads and sampling material |   24 Fr. |
|  |  |
| If conducted without being requested by another service provider, comprising:|    – analysis and report to the authorities under Article 12 paragraph 2 EpidA, if the number of analyses conducted in Switzerland and Liechtenstein during a calendar week amounts to: |   87 Fr. |
| |    – < 100 000 |   82 Fr. |
| |    – 100 000 – < 150 000 |   74 Fr. |
| |    – 150 000 – < 200 000 |   70 Fr. |
| |    – > 200 000 |   64 Fr. |
| |    – ordering processing, overheads and sampling material |     5 Fr. |
|  |  |

#### [1. 2 Pooled molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e197)


|    1.2.1 The Confederation shall pay the costs of pooled molecular-biological analyses for Sars-CoV-2 only as part of outbreak investigation and control procedures ordered by a doctor.  
|    1.2.2 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample, by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA;


|    b. when an analysis is conducted, by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.


|    1.2.3 It shall pay a maximum of 315 francs for pooled molecular-biological analyses for Sars-CoV-2. This amount covers the following services and cost components:  
|    a. for collecting a sample:





|  |  |
| --- | --- |
| Service | Maximum amount |
| Patient consultation and taking sample, including protective materials | 22.50 Fr. |
| For supervising the taking of the sample by the person tested and assigning the sample to the person concerned | 15 Fr. |
|  |  |


|    b. for the pooled molecular-biological analysis:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If conducted on behalf of another service provider, comprising: | 274 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – ordering processing, overheads and sampling material |   24 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25 |     8 Fr. |
|  |  |
| If conducted without being requested by another service provider, comprising: | 255 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – ordering processing, overheads and sampling material |   5 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25 |   8 Fr. |
|  |  |


|    c. for centralised pooling: 



|  |  |
| --- | --- |
| Service | Maximum amount |
| When conducted at compulsory school level and at upper secondary level in cases under Number 1.2.1 for the creation of each pool  | 18.50 Fr. |
|  |  |

#### [1.3 Analyses for Sars-CoV-2 antibodies](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e93)


|    1.3.1 The Confederation shall pay the costs of analyses for Sars-CoV-2 antibodies:  
|    a. if instructed to do so by the responsible cantonal body;  
|    b. if instructed to do so by a doctor four weeks after full vaccination in accordance with FOPH recommendations in the case of persons with severe immodeficiency;  
|    c. if instructed to do so by a doctor with a view to deciding whether a specific person should undergo therapy with monoclonal antibodies.


|    1.3.2 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample, by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA;


|    b. when an analysis is conducted, by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.


|    1.3.3 It shall pay a maximum of 96.50 francs for the analysis for Sars-CoV-2 antibodies. This amount covers the following services and cost components:  
|    a. for collecting a sample:





|  |  |
| --- | --- |
| Service | Maximum amount |
| Patient consultation and taking sample,including protective materials | 22.50 Fr. |
| Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA |   2.50 Fr. |
| Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
|  |  |


|    b. for the analysis for Sars-CoV-2 antibodies:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If conducted on behalf of another service provider, comprising: | 49 Fr. |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA | 25 Fr. |
| |    – ordering processing, overheads and sampling material | 24 Fr. |
|  |  |
| If conducted without being requested by another service provider, comprising: | 30 Fr. |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA | 25 Fr. |
| |    – ordering processing, overheads and sampling material |   5 Fr. |
|  |  |

#### [1.4 Immunological analyses for Sars-CoV-2 antigens and Sars-CoV-2 rapid tests for specialist use](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e94)


|    1.4.1. The Confederation shall pay the costs of immunological analyses for Sars-CoV-2 antigens and for Sars-CoV-2 rapid tests for specialist use.   
|    1.4.2 ...  
|    1.4.3 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample and conducting an analysis, by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,




|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA.


|    1.4.4 It shall pay a maximum of 88.50 francs for immunological analyses for Sars-CoV-2 antigens and for Sars-CoV-2 rapid tests for specialist use. This amount includes the following services and cost components:  
|    a. for collecting a sample:





|  |  |
| --- | --- |
| Service | Maximum amount |
| Patient consultation and taking sample, including protective materials | 22.50 Fr. |
| Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA and requesting the activation code generated by the PT system when infection is detected and for issuing the COVID-19 test or recovery certificate |   2.50 Fr. |
| Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
|  |  |


|    b. for the immunological analysis for Sars-CoV-2 antigens and for a Sars-CoV-2 rapid test for specialist use:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If carried out without being requested by another authorised service provider, comprising: | 11 Fr.  |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA |  6 Fr. |
| |    – ordering processing |   5 Fr. |
|  |  |
| If carried out on behalf of another authorised service provider, comprising: | 30 Fr. |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA |  6 Fr. |
| |    – order processing, overheads and samplingmaterials | 24 Fr. |
|  |  |

#### [1.5 Molecular-biological detection of one or more Sars-CoV-2 variants of concern](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e95)


|    1.5.1 On the order of the competent cantonal authority and provided the results lead to specific measures by the canton, the Confederation shall, if a molecular-biological analysis produces a positive result, pay the costs of the molecular-biological detection of one or more Sars-CoV-2 variants of concern (VOCs), but only.  
|    1.5.2 It shall pay the costs only if the services are provided by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.  
|    1.5.3 On the order of the competent cantonal authority, molecular biological detection may be carried out by one of the following methods:  
|    a. mutation-specific PCR testing;   
|    b. partial genome sequencing. 


|    1.5.4 It shall pay 106 francs for the molecular-biological detection of one or more Sars-CoV-2 variants of concern. The amount covers the following services and cost components:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If carried out without being requested by another authorised service provider, for the analysis and report to the authorities under Article 12 paragraph 2 EpidA | 82 Fr. |
| If carried out on behalf of another service provider, comprising: | 106 Fr. |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA | 82 Fr. |
| |    – order processing, overheads and sampling materials | 24 Fr. |
|  |  |

#### [1.6 Diagnostic sequencing for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e96)


|    1.6.1 The Confederation shall pay the costs of diagnostic sequencing for Sars-CoV-2 2 by means of whole genome sequencing only if ordered by the competent cantonal authority and only in the following cases:  
|    a. in cases where there is reasonable suspicion of the presence of a Sars-CoV-2 variant, in particular in the case of specific severe cases in hospitals and in selected cases in persons suffering from severe immunosuppression;  
|    b. the targeted sequencing of samples in the case of outbreaks in hospitals, homes for the elderly and care homes;  
|    c. targeted and random sequencing in the event of major outbreaks.


|    1.6.2 It shall pay the costs only if the services are provided by:  
|    a. micro-biological diagnostic laboratories that hold a licence under Article 16 EpidA;  
|    b. reference laboratories that meet the requirements of Article 17 EpidA.


|    1.6.3 It shall pay a maximum of 221 francs for sequencing for Sars-CoV-2. The amount covers the following services and cost components:



|  |  |
| --- | --- |
| Service | Maximum amount |
| Conduct of the analysis, comprising: | 221 Fr. |
| |    – analysis and report to the authorities under Article 12 paragraph 2 EpidA | 197 Fr. |
| |    – order processing, overheads and samplingmaterials |   24 Fr. |
|  |  |

#### [1.7 Pooled molecular-biological analyses for Sars-CoV-2 for individual persons](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_1/lvl_d4e97)


|    1.7.1 The Confederation shall pay the costs of pooled molecular-biological saliva analyses for Sars-CoV-2:  
|    a. in the case of the individual participation of persons who are asymptomatic;  
|    b. in testing arranged by the FOPH to monitor the spread of Sars-CoV-2.


|    1.7.2 It shall pay the costs only if the services are provided by the following service providers:  
|    a. for the supervision of the person being tested when taking the sample by:  
|    1. the following service providers under the HIA:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories in accordance with Article 54 paragraph 3 HIO and hospital laboratories in accordance with Article 54 paragraph 2 HIO that hold a licence in accordance with Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,




|    b. when an analysis is conducted, by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.


|    1.7.3 In the case of pooled molecular-biological analyses for Sars-CoV-2 for individual persons, it shall pay a maximum of 36 francs. The amount covers the following services and cost components:  
|    a. for taking the sample:





|  |  |
| --- | --- |
| Service | Maximum amount |
| For supervising the taking of the sample by the person tested and assigning the sample to the person concerned |   15 Fr. |
| For reporting the test result to the person tested and issuing the COVID-19 test certificate |     2.50 Fr. |
|  |  |


|    b. for pooled molecular-biological analyses for individual persons:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If carried out on behalf of another authorised service provider, comprising: |   16 Fr. |
| |    – for the analysis |   13 Fr. |
| |    – order processing, overheads and samplingmaterials |     3 Fr. |
|  |  |
| If carried out on behalf of another authorised service provider, comprising: |   13.50 Fr. |
| |    – for the analysis |   13 Fr. |
| |    – order processing, overheads and samplingmaterials |     0.50 Fr. |
|  |  |


|    c. for centralised pooling: 



|  |  |
| --- | --- |
| Service | Maximum amount |
| For organising the pool, per person |     2.50 Fr. |
|  |  |

### [2 Reduced tariff for targeted and repetitive testing](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_2)

#### [2.1 Sars-CoV-2 rapid tests rapid tests for specialist use](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_2/lvl_d4e100)


|    2.1.1 The Confederation shall pay the costs of Sars-CoV-2 rapid tests for specialist use only in following cases:  
|    a. …  
|    b. in situations with a significantly higher probability of transmission, provided the responsible authority or organisation in the canton makes provision for this and submits a plan to the FOPH;  
|    c. in relation to testing over a limited period in connection with uncontrolled outbreaks of infection, provided the responsible authority or organisation in the canton makes provision for this;


|    2.1.2 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample and conducting an analysis, by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA.




|    2.1.3 It shall pay shall pay a maximum of 30.50 francs for a Sars-CoV-2-rapid test for specialist use. The amount covers the following services and cost components:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If the sample is not taken by the tested person him- or herself: taking the sample and conducting a test, including the test materials, the protective materials and working time, and for the analysis and order processing | 28 Fr. |
| If the sample is taken by the tested person him- or herself: taking the sample and conducting a test, including the test materials, the protective materials and working time, and for the analysis and order processing | 14 Fr. |
| For issuing the COVID-19 test or recovery certificate |     2.50 Fr. |
|  |  |

#### [2.2 Pooled molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_2/lvl_d4e101)


|    2.2.1 The Confederation shall pay the costs of pooled molecular-biological analyses for Sars-CoV-2 only in following cases:  
|    a. …  
|    b. in situations with a significantly higher probability of transmission, provided the responsible authority or organisation in the canton makes provision for this and submits a plan to the FOPH or provided the testing is coordinated via a platform made available by the Confederation;  
|    c. in relation to testing over a limited period in connection with uncontrolled outbreaks of infection, provided the responsible authority or organisation in the canton makes provision for this or provided the testing is coordinated via a platform made available by the Confederation;


|    2.2.2 It shall pay the costs only if the services are provided:  
|    a. when collecting a sample and conducting an analysis, by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton,  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment,  
|    4. assistants as defined in the InvIA;


|    b. it shall pay the costs only if the services are provided by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.


|    2.2.3 It shall pay a maximum of 311.50 francs for pooled molecular-biological analyses for Sars-CoV-2. The amount covers the following services and cost components:  
|    a. for collecting a sample: 





|  |  |
| --- | --- |
| Service | Maximum amount |
| Taking the sample, including the protective materials and working time | 16.50 Fr. |
|  |  |


|    b. for the pooled molecular-biological analysis:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If conducted on behalf of another service provider, comprising: | 274 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – ordering processing, overheads and sampling material |   24 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25 |     8 Fr. |
|  |  |
| If conducted without being requested by another service provider, comprising: | 255 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – ordering processing, overheads and sampling material |     5 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25 |     8 Fr. |
|  |  |


|    c. for centralised pooling: 



|  |  |
| --- | --- |
| Service | Maximum amount |
| When conducted at compulsory school level, at upper secondary level and at school camps, for the creation of each pool  | 18.50 Fr. |
|  |  |


|    d. for the certificate:



|  |  |
| --- | --- |
| Service | Maximum amount |
| For issuing the COVID-19 test certificate |     2.50 Fr. |
|  |  |

### [3 Basic tariff for targeted and repetitive testing](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_3)

#### [3.1 Sars-CoV-2 rapid tests for specialist use](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_3/lvl_d4e103)


|    3.1.1 The Confederation shall pay the costs of Sars-CoV-2 rapid tests for specialist use only in following cases:  
|    a. where targeted and repetitive testing is carried out in hospitals, homes for the elderly and care homes and other socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment;  
|    b. where targeted and repetitive testing is carried out in companies specified by the cantons that are important for the operation of critical infrastructure, provided the responsible authority or organisation in the canton submits a plan to the FOPH or provided that the testing is coordinated via a platform made available by the Confederation;  
|    c. in testing arranged by the FOPH to monitor the spread of Sars-CoV-2.


|    3.1.2 ...  
|    3.1.3 It shall pay the costs of Sars-CoV-2 rapid tests for specialist use under section 3.1.1 only if the services are provided by:  
|    1. the following service providers under the Health Insurance Act:  
|    – doctors  
|    – pharmacists  
|    – hospitals  
|    – laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA  
|    – care homes  
|    – organisations that provide nursing services and other assistance at home,


|    2. test centres operated by or on behalf of a canton;  
|    3. socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment;  
|    4. assistants as defined in the InvIA.


|    3.1.4 It shall pay a maximum of 8.50 francs for a Sars-CoV-2 rapid test for specialist use under section 3.1.1. This amount covers the following services and cost components:



|  |  |
| --- | --- |
| Service | Maximum amount |
| Conducting the Sars-CoV-2 rapid test for specialist use, test materials only |  6.00 Fr. |
| For issuing the COVID-19 test or recovery certificate |     2.50 Fr. |
| s |  |

#### [3.2 Pooled molecular-biological analyses for Sars-CoV-2](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_3/lvl_d4e104)


|    3.2.1 The Confederation shall pay the costs of pooled molecular-biological analyses for Sars-CoV-2 only in following cases:  
|    a. where targeted and repetitive testing is carried out in hospitals, homes for the elderly and care homes and other socio-medical institutions that admit persons for treatment or care, for rehabilitation or for socio-professional rehabilitation or employment;  
|    b. where targeted and repetitive testing is carried out in businesses specified by the cantons that are important for the operation of critical infrastructure, provided the responsible authority or organisation in the canton submits a plan to the FOPH or provided the testing is coordinated via a platform made available by the Confederation;  
|    c. in testing arranged by the FOPH to monitor the spread of Sars-CoV-2.


|    3.2.2 It shall pay the costs only if the services are provided by laboratories under Article 54 paragraph 3 HIO and hospital laboratories under Article 54 paragraph 2 HIO that are licensed under Article 16 paragraph 1 EpidA.  
|    3.2.3 It shall pay a maximum of 295 francs for pooled molecular-biological analyses for Sars-CoV-2. The amount covers the following services and cost components:



|  |  |
| --- | --- |
| Service | Maximum amount |
| If conducted on behalf of another service provider, comprising: | 274 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – order processing, overheads and sampling materials |   24 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25|    – for conducting a centralised pool in cases under number 3.2.1 letters b and c for the creation of each pool |        8 Fr.  18.50 Fr. |
|  |  |
| If conducted without being requested by another service provider, comprising: | 255 Fr. |
| |    – analysis with a minimum pool size of 4 |   82 Fr. |
| |    – order processing, overheads and sampling materials |     5 Fr. |
| |    – surcharge for additional sampling up to a maximum pool size of 25|    – for conducting a centralised pool in cases under number 3.2.1 letters b and c for the creation of each pool |     8 Fr.18.50 Fr. |
|  |  |
| For issuing the COVID-19 test certificate |     2.50 Fr. |
|  |  |

### [4 Limitations](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_6/lvl_d4e89/lvl_4)


|    4.1 If both a molecular-biological analysis for Sars-CoV-2 in accordance with number 1.1 and an analysis for Sars-CoV-2 antibodies in accordance with number 1.3 are carried out on the same person on the same day, the Confederation shall make only one payment of the amount due for collecting a sample in accordance with number 1.1.3 letter a and 1.3.3 letter a and the amount due for the order processing, overheads and sampling materials in accordance with the number 1.1.3 letter b and 1.3.3 letter b.  
|    4.2 ...  
|    4.3 If both a molecular-biological analysis for Sars-CoV-2 in accordance with number 1.1 and the molecular-biological detection of one or more Sars-CoV-2 variants of concern in accordance with number 1.5 or sequencing for Sars-CoV-2 in accordance with number 1.6 are carried out by the same service provider, the Confederation shall make only one payment in respect of its share of the costs for order processing and overheads in accordance with numbers 1.1.3 letter b and 1.5.3 letter a or 1.6.3.  
|    4.4 In the case of analyses for Sars-CoV-2, where the person tested can take the sample, no charge may be made for collecting a sample.

# [Annex 7](https://www.fedlex.admin.ch/eli/cc/2020/438/en#annex_7)

